《大行報告》瑞信下調同程旅行(00780.HK)目標價至16元 下調盈測反映封城影響及前景較疲弱
瑞信發表研究報告,預測同程旅行(00780.HK)第三季收入按年增長5%至20億元人民幣,處於增長指引的下限,並預期經調整淨利潤達到2.53億元人民幣,按年跌29%。
該行指,8月下旬新一輪疫情影響第三季收入,9月至10月整體旅行需求低迷,相信超出預期的需求疲軟將影響利潤率表現。考慮到第四季及明年行業前景較弱,相信經營環境將充滿挑戰。
瑞信將同程2022至2024年每股盈利預測下調20.5%、11.8%及8.5%,以反映近期封城措施的影響和行業前景較弱,目標價從18.6元下調至16元,維持「跑贏大市」評級,而行業首選為攜程(09961.HK)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.